日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Proliferation and Apoptosis Adaptor Protein 15 (PEA15), a Potential Oncogenic Regulator of VHL and HIF1A Identified through Proteomic Analysis in Hepatocellular Carcinoma.

通过肝细胞癌蛋白质组学分析发现，增殖和凋亡衔接蛋白 15 (PEA15) 是 VHL 和 HIF1A 的潜在致癌调节因子。

期刊:Cancer Communications
影响因子:24.9
doi:10.34133/cancomm.0020
Jeong Yun Seong, Shin Ji-Hyun, Kim Soo Mi, Sohn Bo Hwa, Yim Sun Young, Kim Ji Hoon, Shim Jae Jun, Lee Sung Hwan, Chun Yun Shin, Lee Sunyoung S, Dai Hui, Kaseb Ahmed, Kang Koo Jeong, Eltzschig Holger K, MacLeod A Robert, Luo Xiaolin, Revenko Alexey, Kim Youngsoo, Lee Ju-Seog
细胞生物学
VHL
HIF1A
Apoptosis
凋亡
发表日期：2026
文献求助 收藏

Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features

整合多组学分析表明，浸润性肝细胞癌是一种具有独特分子特征的免疫治疗耐药亚型。

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2025.0792
Lee, Won Suk; Woo, Seonjeong; Lee, Sung Hwan; Jo, Gae Hoon; Kim, Ilhwan; Kim, Hyeyeong; An, Chansik; Jung, Sanghoon; Kim, Gwangil; Kang, Haeyoun; Kang, Beodeul; Kim, Jung Sun; Lim, Ho Yeong; Kang, Incheon; Yang, Hannah; Kong, So Jung; Son, Dahyeon; Shin, Dong Jun; Kwon, Woo Young; Lee, Da-Yeon; Lee, Ju-Seog; Park, Junho; Kim, Youngsoo; Hwang, Sohyun; Kim, Chan; Chon, Hong Jae
肿瘤
肿瘤免疫
治疗耐药
细胞生物学
免疫/内分泌
发表日期：2026
文献求助 收藏

Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach

利用转录组学和基因组学方法识别索拉非尼对肝细胞癌患者的获益

期刊:Jhep Reports
影响因子:7.5
doi:10.1016/j.jhepr.2026.101742
Yim, Sun Young; Kim, Hayeon; Kim, Tae Hyung; Kang, Sang-Hee; Lee, Youngwoo; Choi, Eunho; Yoo, Yang Jae; Kang, Seong Hee; Lee, Young-Sun; Jung, Young Kul; Seo, Yeon Seok; Yim, Hyung Joon; Yeon, Jong Eun; Yang, Kyung Suk; Tang, Yitao; Sohn, Bowha; Jeong, Yun Seong; Park, Hyewon; Liang, Han; Lee, Ju-Seog; Kim, Ji Hoon
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Evolving Molecular Subtypes of Gastric Cancer: From Past Classifications to Present Consensus and Future Directions for Precision Therapy

胃癌分子亚型演变：从过去的分类到目前的共识以及精准治疗的未来方向

期刊:Journal of Gastric Cancer
影响因子:3.8
doi:10.5230/jgc.2026.26.e12
Lee, Ju-Seog
胃癌
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Fructose and glucose from sugary drinks enhance colorectal cancer metastasis via SORD

含糖饮料中的果糖和葡萄糖通过SORD途径促进结直肠癌转移。

期刊:Nature Metabolism
影响因子:20.8
doi:10.1038/s42255-025-01368-w
Feng, Tianshi; Luo, Qin; Liu, Yanlin; Jin, Zeyu; Skwarchuk, David; Lee, Rumi; Nam, Miso; Asara, John M; Adye, Daya R; Lorenzi, Philip L; Tan, Lin; Pei, Guangsheng; Zhao, Zhongming; Zarrin-Khameh, Neda; Paulucci-Holthauzen, Adriana; Simons, Brian W; Lee, Ju-Seog; Kopetz, Scott; Yun, Jihye
肿瘤
肠癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"

致编辑的信函，主题为“基因组生物标志物预测肝细胞癌患者对阿特珠单抗联合贝伐珠单抗免疫疗法的反应：来自IMbrave150试验的启示”

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2024.0828
Lee, Sung Hwan; Yim, Sun Young; Kim, Ji Hoon; Lee, Sunyoung S; Kaseb, Ahmed O; Wei, Peng; Lee, Ju-Seog
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial"

致编辑的信函，主题为“基因组生物标志物预测肝细胞癌患者对阿特珠单抗联合贝伐珠单抗免疫疗法的反应：来自IMbrave150试验的启示”

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2024.0830
Yim, Sun Young; Lee, Sung Hwan; Kim, Ji Hoon; Lee, Sunyoung S; Kaseb, Ahmed O; Lee, Ju-Seog
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Correspondence to editorial 1 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial"

致编辑的信函 1，主题为“基因组生物标志物预测肝细胞癌患者对阿特珠单抗联合贝伐珠单抗免疫疗法的反应：来自 IMbrave150 试验的启示”

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2024.0829
Lee, Sung Hwan; Yim, Sun Young; Kim, Ji Hoon; Lee, Sunyoung S; Kaseb, Ahmed O; Lee, Ju-Seog
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823]

对“基因组生物标志物预测肝细胞癌患者对阿特珠单抗联合贝伐珠单抗免疫疗法的反应：来自 IMbrave150 试验的见解”[Clin Mol Hepatol 2024;30:807-823]的勘误

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2024.0333e
Yim, Sun Young; Lee, Sung Hwan; Baek, Seung-Woo; Sohn, Bohwa; Jeong, Yun Seong; Kang, Sang-Hee; Park, Kena; Park, Hyewon; Lee, Sunyoung S; Kaseb, Ahmed O; Park, Young Nyun; Leem, Sun-Hee; Curran, Michael A; Kim, Ji Hoon; Lee, Ju-Seog
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Epigenetic modulation of BARD1 to enhance anti-VEGF therapy.

通过表观遗传调控BARD1来增强抗VEGF疗法。

期刊:Cell Reports Medicine
影响因子:10.6
doi:10.1016/j.xcrm.2025.102329
Bayraktar Emine, Rodriguez-Aguayo Cristian, Stur Elaine, Kumar Sudhir, Mangala Lingegowda S, Jennings Nicholas B, Bayram Nazende Nur, Corvigno Sara, Asare Amma, Ivan Cristina, Kim Mark S, Vu Thanh Chung, Hanjra Pahul, Kim Sangbae, Ahumada Adrian Lankenau, Wu Weichem, Lee Sanghoon, Szymanowska Anna, Oztatlici Hulya, Estecio Marcos R, Lee Ju-Seog, Jain Abhinav K, Sahni Nidhi, Hagan John P, Baylin Stephen, Liu Jinsong, Lopez-Berestein Gabriel, Pradeep Sunila, Sood Anil K
EGF
VEGF
BARD1
发表日期：2025
文献求助 收藏